Dipeptidyl Peptidase 4 Inhibitors Pipeline Research Report 2021 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Dipeptidyl Peptidase 4 Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
This "Dipeptidyl peptidase 4 inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Dipeptidyl peptidase 4 inhibitors pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The companies and academics are working to assess challenges and seek opportunities that could influence Dipeptidyl peptidase 4 inhibitors R&D. The therapies under development are focused on novel approaches for Dipeptidyl peptidase 4 inhibitors.
Dipeptidyl peptidase 4 inhibitors Emerging Drugs Chapters
This segment of the Dipeptidyl peptidase 4 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Dipeptidyl peptidase 4 inhibitors Emerging Drugs
HSK7653: Haisco Pharmaceutical Group
HSK7653 is a new oral drug for the treatment of type 2 diabetes with independent intellectual property rights developed by Haisco. It is intended to be used for the treatment of type 2 diabetes. HSK7653, as a long-acting inhibitor of dipeptidyl peptidase-4 (DPP-4), can increase the plasma levels of endogenous glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) Concentration, promotes insulin secretion in a glucose concentration-dependent manner, and ultimately improves blood sugar control.
It is currently in Phase III stage of development and is being developed by Haisco Pharmaceutical Group.
DA-1229: Dong-A ST
DA-1229 is an orally available small molecule agonist of the thyroid hormone receptor that is being approved for Type 2 diabetes mellitus but it is currently in Phase II stage of development for the treatment of Calcific Aortic Valve Disease and is being developed by Dong-A ST.
Dipeptidyl peptidase 4 inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Dipeptidyl peptidase 4 inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Major Players working on Dipeptidyl peptidase 4 inhibitors
There are approx. 8+ key companies which are developing the Dipeptidyl peptidase 4 inhibitors. The companies which have their Dipeptidyl peptidase 4 inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Haisco Pharmaceutical Group.
This report covers around 8+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Dipeptidyl peptidase 4 inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Dipeptidyl peptidase 4 inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Dipeptidyl peptidase 4 inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dipeptidyl peptidase 4 inhibitors drugs.
Dipeptidyl peptidase 4 inhibitors Report Insights
- Dipeptidyl peptidase 4 inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Dipeptidyl peptidase 4 inhibitors Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Scenario and Emerging Therapies:
- How many companies are developing Dipeptidyl peptidase 4 inhibitors drugs?
- How many Dipeptidyl peptidase 4 inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Dipeptidyl peptidase 4 inhibitors?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Dipeptidyl peptidase 4 inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Dipeptidyl peptidase 4 inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Boehringer Ingelheim
- Haisco Pharmaceutical Group
- BioXcel Therapeutics
- Dong-A ST
- CSPC ZhongQi Pharmaceutical Technology
- Chia Tai Tianqing Pharmaceutical Group
- BXCL 701
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/q19uwp
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900